Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Corcept Therapeutics Incorporated    CORT

CORCEPT THERAPEUTICS INCORPORATED

(CORT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Corcept Therapeutics Incorporated : Appoints Gillian M. Cannon, PhD, to Board of Directors

11/24/2020 | 08:46am EST

MENLO PARK - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors.

Dr. Cannon brings to Corcept more than 30 years experience in the pharmaceutical industry, where she has served in leadership roles at Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. In her 27-year career at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck's start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck's specialty products franchise and Global Commercial Head of its neuroscience franchise. She is currently President of Alyvant and Executive in Residence for Roivant Sciences.

'I am very pleased to welcome Gillian to our board,' said Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. 'Her extensive experience in pharmaceutical commercial operations, marketing and sales and her track record of devising and gaining acceptance for innovative solutions will help us advance our pipeline of proprietary, selective cortisol modulators.'

About Corcept Therapeutics

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business and achieve our goals and conduct our clinical trials during the Covid-19 pandemic and to generate sufficient revenue to fund our commercial operations and development programs; the availability of competing treatments, including generic versions of Korlym; our ability to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym and risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates and oversight, and other requirements. These and other risks are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include statements regarding advancement of our pipeline of proprietary, selective cortisol modulators. We disclaim any intention or duty to update forward-looking statements made in this press release.

Contact:

Christopher S. James

Tel: 650-684-8725

Email: cjames@corcept.com

Web: www.corcept.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CORCEPT THERAPEUTICS INCORPORATED 1.88% 28.14 Delayed Quote.7.57%
MERCK & CO., INC. 1.47% 83.38 Delayed Quote.1.93%
All news about CORCEPT THERAPEUTICS INCORPORATED
2020INSIDER TRENDS : Corcept Therapeutics Insider Converts Option/Derivative Securit..
MT
2020HC Wainwright Adjusts Corcept Therapeutics' Price Target to $32 From $22, Kee..
MT
2020CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
2020CORCEPT THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
2020CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
2020Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors
GL
2020AFTER HOURS WATCH LIST SCORECARD : Cort, sono, zto
MT
2020SECTOR UPDATE : Health Care Stocks Back Near Even At Thursday Close
MT
2020Modest Decline for Health Care Stocks This Afternoon
MT
2020SECTOR UPDATE : Health Care
MT
More news
Financials (USD)
Sales 2020 358 M - -
Net income 2020 102 M - -
Net Debt 2020 - - -
P/E ratio 2020 34,7x
Yield 2020 -
Capitalization 3 269 M 3 269 M -
Capi. / Sales 2020 9,12x
Capi. / Sales 2021 8,11x
Nbr of Employees 206
Free-Float 86,4%
Chart CORCEPT THERAPEUTICS INCORPORATED
Duration : Period :
Corcept Therapeutics Incorporated Technical Analysis Chart | CORT | US2183521028 | MarketScreener
Technical analysis trends CORCEPT THERAPEUTICS INCORPORATED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 25,75 $
Last Close Price 28,14 $
Spread / Highest target 13,7%
Spread / Average Target -8,49%
Spread / Lowest Target -43,1%
EPS Revisions
Managers and Directors
NameTitle
Joseph K. Belanoff President, Chief Executive Officer & Director
James N. Wilson Chairman
Gary Charles Robb Secretary & Chief Financial Officer
Hazel Hunt Senior Vice President-Research
Andreas Grauer Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CORCEPT THERAPEUTICS INCORPORATED7.57%3 269
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993